Horizon Pharma’s $345 Million Follow-On Offering

Davis Polk advised the underwriters in connection with the $345 million public offering of ordinary shares of Horizon Pharma plc. Horizon’s ordinary shares are listed on the NASDAQ Global Select Market under the symbol “HZNP.”

Citigroup Global Markets Inc., Morgan Stanley & Co. LLC, Goldman Sachs & Co. LLC and Cowen and Company, LLC acted as underwriters in the deal.

Horizon Pharma plc is a specialty biopharmaceutical company focused on researching, developing and commercializing innovative medicines that address unmet treatment needs for rare and rheumatic diseases. Horizon Pharma’s global headquarters are in Dublin, Ireland.

The Davis Polk corporate team included partner Alan F. Denenberg (Picture) and associates Jeffrey C. Lau, Katherine Schloss Ackerman and Caitlin Moyles Cunnane. Partner Rachel D. Kleinberg provided tax advice. The intellectual property and technology team included partner David R. Bauer and associates Michael V. Policastro and Jay Frankel. Associate J. Taylor Arabian provided 1940 Act advice.

Involved fees earner: Taylor Arabian – Davis Polk & Wardwell; David Bauer – Davis Polk & Wardwell; Alan Denenberg – Davis Polk & Wardwell; Jay Frankel – Davis Polk & Wardwell; Rachel Kleinberg – Davis Polk & Wardwell; Jeffrey Lau – Davis Polk & Wardwell; Caitlin Moyles Cunnane – Davis Polk & Wardwell; Michael Policastro – Davis Polk & Wardwell; Katherine Schloss Ackerman – Davis Polk & Wardwell;

Law Firms: Davis Polk & Wardwell;

Clients: Citigroup Global Markets Ltd; Cowen and Company; Goldman Sachs & Co.; Morgan Stanley;


Author: Ambrogio Visconti